AGIO Stock Ownership Breakdown

A company's 13F filings with the Securities and Exchange Commission (SEC) provides investors with comprehensive information about institutional ownership in a listed company, a sign of strength in terms of how many institutions have confidence in that company. The number of institutional investors who currently own AGIO shares is 306, representing 106.33% of the company's common stock.

BANK OF NEW YORK MELLON CORP, in the last quarter, reduced its stake in AGIO by -3.83% restricting it's holding to 195.96 thousand shares of worth nearly $5.73M. GOLDMAN SACHS GROUP INC also lessened -11.24% of the AGIO shares from its portfolio, reducing its holding to 539.58 thousand shares of worth $15.78M. NORTHERN TRUST CORP also shunned AGIO shares holding by -4.8% last quarter which brought its holding to 590.49 thousand shares worth $17.27M.

As per its latest 13F filing, BANK OF AMERICA CORP /DE/ increased its stake in AGIO by 85.35% in the last quarter. The institutional holder raised its holding to 381.73 thousand shares having worth more than $11.16M. UBS GROUP AG also added 9,117.1% more shares of AGIO to its portfolio, raising its holding to 170.89 thousand shares of worth $5.00M. ASSENAGON ASSET MANAGEMENT S.A. also increased its AGIO shares holding by 800.52% which brought its holding to 454.8 thousand shares worth $13.30M.

The insider with the most stakes in AGIO is CELGENE CORP /DE/ , 10 percent owner at the company. Additionally, AGIO stock is highly held by director FOUSE JACQUALYN A and director Schenkein David P among others.

Company executives, directors, and other insiders own 1.51% percent of Agios Pharmaceuticals, Inc.'s stock. Within the last six months, there have been 7 transaction(s) in which AGIO insiders have sold stock, totaling 28.92K shares. Insiders that have sold shares include MILANOVA TSVETA, WASHBURN THEODORE JAMES JR., and BALLAL RAHUL D..

There have been 0 transaction(s) during the past 6-months in which Agios Pharmaceuticals, Inc. insiders have bought stock, totalling 0 shares

Around 150.35K Agios Pharmaceuticals, Inc. shares are held by insiders, which represents about 1.51% of AGIO stock.

AGIO 10 percent owner, CELGENE CORP /DE/ holds the largest portfolio of the company's shares. AGIO shares owned by CELGENE total nearly 1.78 million.

BANK OF AMERICA CORP /DE/ is the largest institutional owner in AGIO which holds 381.73 thousand shares worth $11.16M or 0.68% of the total AGIO shares outstanding followed by BANK OF NEW YORK MELLON CORP with ownership of 195.96 thousand shares representing 0.35% of the AGIO ownership. UBS GROUP AG is the third largest stakeholder with 170.89 thousand shares or 0.31% of the ownership worth more than $5.00M.

Stock options give the owner the ability but not the obligation to buy or sell a security at a predetermined price and date. Stock options can be classified into two types: puts and calls. A put is a bet on falling stock, and a call is a bet on rising stock. As far as the AGIO is concerned, it is a stock which is optionable.

Number of AGIO shares short is 5.53M. Shares short is a market sentiment in which investors have sold their shares short in a given stock but have not yet covered them or closed them out.

As of today, 57.03M shares of AGIO are outstanding.

Float represents the number of tradeable shares in a specific stock. By subtracting restricted and closely-held shares from a firm's total outstanding shares, we can calculate its floating stock. The term "closely-held shares" refers to shares held by employees, major shareholders, and company insiders. At present, AGIO has 50.51M shares in float.

Short ratio is calculated by dividing the number of short shares, short interest or bets that shareholders will sell short from the average daily volume. A higher ratio indicates longer times needed to repurchase borrowed shares (sold). The short ratio for AGIO is 4.79.